Clinical trial
Treatment Use Study With Sunitinib (SU011248) For Patients With…
NCT00130897 · Pfizer, Industry · Approved for marketing
Key facts
| NCT number | NCT00130897 |
|---|---|
| Title | Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma |
| Official title | A SU011248 Expanded Access Protocol For Systemic Therapy Of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248 |
| Lead sponsor | Pfizer, Industry |
| Status | Approved for marketing |
| Study type | Expanded Access |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Sutent |
| Start date | Jul 1, 2005 |
| Primary completion | Nov 1, 2011 |
| Completion | Nov 1, 2011 |
| First posted | Aug 16, 2005 |
| Last update posted | Mar 9, 2012 |
| Countries | Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia and 38 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: